Investor Relations

Overview

AnaptysBio is a clinical-stage antibody development company advancing therapeutic antibody product candidates focused on unmet medical needs in inflammation.

read more

Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

AnaptysBio and GlaxoSmithKline Amend Strategic Immuno-Oncology Collaboration

Dostarlimab royalties to AnaptysBio increase from 4-8% to 8-25% of global net sales, with first US approval in endometrial cancer anticipated in Q4 2020 Additional 1% royalty to AnaptysBio on GSK’s global net sales of Zejula™ (niraparib) starting January 2021 GSK to pay one-time cash payment of

AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)

6 of 8 patients achieved primary endpoint of improvement in the clinical global impression scale (CGI) on Day 29, with rapid reduction of skin pustules by 60% on Day 8 and 94% clearance on Day 29 FDA end-of-Phase 2 meeting anticipated in Q4 2020 to outline registration path of imsidolimab for the

AnaptysBio to Present at the 2020 Cantor Global Virtual Healthcare Conference

SAN DIEGO , Sept. 11, 2020 (GLOBE NEWSWIRE) -- AnaptysBio , Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that Hamza Suria, chief executive officer of AnaptysBio, will